Performance Enhancing Drugs Market Players, Competitive Landscape, Demand and Trends by Forecast to 2030
Market Analysis
The Performance
Enhancing Drugs Market is anticipated to reach USD 534.3 Million by 2030 at
6.6% CAGR during the forecast period 2022-2030, as per the latest Market
Research Future (MRFR) report. Performance enhancing drugs, simply put, are
different substances, procedures, or chemical agents that are designed to offer
advantages during athletic performance. These drugs affect the body in various
ways, such as increasing the oxygen-carrying capacity of the blood and also
enlarge muscles. Performance enhancing drugs helps the body in recovering from
workouts quickly. This drug can be taken as a topical treatment, injection, or
a pill.
Various factors are propelling the performance enhancing
drugs market growth. These factors, as stated by the MRFR report, include
rising use of anabolic steroids to treat various medical conditions such as
anemia, pain management, and certain types of breast cancer, availability of
huge funds for research and development activities, and various benefits for
athletes such as muscle enlargement and increased blood’s oxygen carrying
capacity.
On the contrary, the use of performance enhancing drugs
leads to numerous side effects such as heart attack and masculinization and
heart attack in females, and diminished sperm production and acne in males.
This may impact the performance enhancing drugs market growth over the forecast
period.
Market Segmentation
The Market Research Future report provides a wide segmental
analysis of the performance enhancing drugs market based on products, types,
and end users.
Based on types, the performance enhancing drugs market is
segmented into nootropic, ergogenic aids, and others. The ergogenic aids
segment is again segmented into human growth hormone, dehydroepiandrosterone
(DHEA), anabolic steroids, and others. The nootropic segment is further
segmented into choline and acetylcholine intermediates, ampakines, racetams, and
others.
Based on products, the performance enhancing drugs market is
segmented into patches, injections,
pills, and others.
Based on end users, the performance enhancing drugs market
is segmented into militaries, students, bodybuilders, athletes, and
others.
Regional Analysis
Based on the region, the performance enhancing drugs market
report covers the latest trends and growth opportunities across Europe, the
Americas, the Asia Pacific (APAC), and the Middle East and Africa. Of these,
the Americas will dominate the market over the forecast period. This is owing
to the presence of well-developed economies having high per capita income, especially
in Canada and the US, the two major contributors of the region. Moreover, the
rising prevalence of breast cancer incidences is likely to push market growth
as anabolic steroids is used for treating various forms of breast cancer.
The performance enhancing drugs market in Europe is
predicted to have the second-largest share in the market over the forecast
period. This is owing to rising acceptance of performance-enhancing drugs in
the region and accessibility of funds for R&D activities.
The performance enhancing drugs market in the APAC region is
predicted to grow at the fastest pace over the forecast period. This is owing
to the presence of immense opportunity in the market, continuously developing
economies, and rising awareness about performance enhancing drugs. Moreover,
immense growth opportunities in this region, the presence of constantly
developing economies, and increasing awareness regarding fitness are also
boosting the market growth.
The performance enhancing drugs market in the Middle East
and Africa is predicted to have the least share in the market over the forecast
period. This is owing to the presence of a poor economy in the African region.
A major part of the market share is held by the Middle East, owing to huge
healthcare expenditure and a well-developed healthcare sector.
Key Players
Leading profiled in the performance
enhancing drugs market players report include Eli Lilly and Company. (US),
Onnit Labs, LLC. (US), Douglas Laboratories. (US), BrainAlert, LLC (US), Novo
Nordisk A/S (Europe), AstraZeneca (Europe), Bayer AG (Europe), Balkan
Pharmaceuticals (Europe), and Taj Pharmaceuticals Limited (India), among
others. The major players in the market have acquired several strategies to
strengthen their position and also create a footprint in the market. These
include acquisitions, partnerships, joint ventures, agreements, high expense on
R&D activities, market initiatives, clinical trials, new product launches,
and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity
of various industries through Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research
(CFR), and Market Research & Consulting Services.
Comments
Post a Comment